RxDoctor Payments DataLook up a doctor →

Murali Chakinala, MD

Pulmonary Disease · Saint Louis, MONPI 1407872724

Payments from drug & device makers

$2,439,479in general payments, 2019–2025

Across 553 payments — averaging $4411.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.1M
  • Janssen Research & Development, LLC$431K
  • Medtronic$302K
  • United Therapeutics Corporation$288K
  • Actelion Pharmaceuticals, Ltd$215K
  • Bayer$45K
  • plus $54K from 11 others

What the payments were for

  • Consulting fees$134,24378%
  • Speaking & faculty fees$3,9602%
  • Travel & lodging$24,08614%
  • Food & beverage$9,9346%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,439,479 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$131,271
Medicare patients
769
Services billed
2,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan829$10,519,049
AdempasRiociguat422$5,892,674
Tyvaso DpiTreprostinil155$3,921,312
Orenitram ErTreprostinil Diolamine165$2,760,452
UptraviSelexipag117$2,752,398
WinrevairSotatercept-Csrk126$2,138,783
Ambrisentan485$1,520,450
LetairisAmbrisentan86$1,056,016
Tadalafil594$480,912
AdcircaTadalafil48$236,700
RemodulinTreprostinil Sodium15$194,104
TreprostinilTreprostinil Sodium11$158,312
JardianceEmpagliflozin133$99,046
VeletriEpoprostenol Sodium12$94,881
Sildenafil Citrate340$91,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan$26,242$13,325,477982 claims
BayerAdempas$44,593$5,892,674422 claims
MerckWinrevair$1,105,925$2,138,783126 claims
United Therapeutics CorporationAdcirca, Remodulin$287,580$430,80463 claims
SandozTreprostinil$614$158,31211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →